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Abstract
Background: Burden of Group A streptococcus (GAS) pharyngitis is scarce in developing countries, still unknown in
China. The objective of this study was to determine the incidence of clinical cases of pharyngitis and GAS culture-
positive pharyngitis, and their outpatient visits among children aged 0–14 years in Beijing, the capital of China.
Methods: Multiplier model was used to estimate the numbers of pharyngitis cases, based on reported numbers of
clinical cases and GAS culture-positive rates from GAS surveillances in Beijing, consultation rate, population
coverage of GAS surveillances, sampling success rate, and test sensitivity of GAS culture from previous studies,
surveys and surveillances.
Results: An average of 29804.6 (95 % CI: 28333.2–31276.0) clinical cases of pharyngitis per 100,000 person-years
occurred among children aged 0–14 years, resulting in correspondingly 19519.0 (95 % CI: 18516.7–20521.2)
outpatient visits per 100,000 person-years from 2012 to 2014 in Beijing. On average, there were 2685.1 (95 % CI:
2039.6–3330.6) GAS culture-positive cases of pharyngitis and 1652.7 (95 % CI: 1256.5–2049.0) outpatient visits per
100,000 person-years during the same period. The estimated burden of GAS pharyngitis was significantly higher
than that of scarlet fever. Children aged 5–14 years had a higher burden of GAS pharyngitis than those aged 0–4 years.
Conclusions: The present data suggests that GAS pharyngitis is very common in children in China. Further studies and
surveillances are needed to monitor trends and the effectiveness of control measures.
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Background
Pharyngitis is one of the most common presenting
symptom for seeking medications, accounting for an es-
timated 15 million outpatient visits in 2006 in United
States [1]. Group A streptococcus (GAS) is the main
bacterial cause of pharyngitis, and responsible for a large
number of pharyngitis cases in children [2]. Although
GAS pharyngitis may seem relatively benign and unim-
portant, it causes enormous use of health resources and
economic costs [3]. Furthermore, the primary infection
can lead to severe GAS diseases (eg, acute rheumatic
fever, rheumatic heart disease, post-streptococcal glom-
erulonephritis, and invasive infection) [4, 5]. A study
reviewed recent population-based data and estimated
that there were 616 million new GAS pharyngitis cases
per year in the world, with an estimated number of more
than 1.78 million new cases and 517,000 deaths of severe
GAS disease each year [5]. It occurs most commonly
among children aged 5–15 years, and its incidence in
children varies from region to region [6]. However, epi-
demiological data on GAS pharyngitis from developing
countries is scarce [4–6]. To our knowledge, the disease
burden is still unknown in China. In this study, we
aimed to determine the incidence of clinical cases of
pharyngitis and GAS culture-positive pharyngitis, and
their outpatient visits among children aged 0–14 years
in Beijing, the capital of China.
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Methods
GAS surveillances in Beijing
GAS surveillances were conducted in the pediatric
clinics of 36 hospitals within Beijing’s 18 districts since
May 2011. Since November 2014, the number of sentinel
hospitals has been cut down from 36 to 17. The surveil-
lance system was designed and managed by Beijing
Center for Disease Prevention and Control. Under the
system, clinicians were required to diagnose scarlet fever
or pharyngitis and to record the weekly numbers of out-
patient visits by age groups (0–4 years, and 5–14 years)
on a fixed form. All children with scarlet fever diagnosed
by clinicians were invited to participate in the study.
Meantime, each week, 10 children with pharyngitis diag-
nosed by clinicians were randomly selected from each
hospital. If there are less than 10 patients in a hospital in
a week, all of them were invited to participate in the
study. The pharyngeal swab samples were collected by
trained clinicians from study participants after their
guardians gave informed consent, and tested by the col-
laborating laboratories. A detailed description of the sur-
veillance was published in a previous study [7].
National notifiable infectious disease surveillance system
in China
Scarlet fever is a notifiable disease according to Law of
the People Republic of China on the Prevention and
Treatment of Infectious Diseases. All clinical cases of
scarlet fever should be reported to the National Notifiable
Infectious Disease Surveillance System (NNIDSS) by clini-
cians and hospitals when they sought medical services in
China.
Case definition
In this study, clinical cases of pharyngitis was defined as
follows: pharyngitis is the inflammation of the back of
the throat including the tonsils, and its common symp-
toms include fever, sore throat, red tonsils, and enlarged
lymph nodes in the neck and so on. Case definition of
clinical cases of scarlet fever conformed to the Diagnostic
Criteria for Scarlet Fever (WS282–2008) enacted by the
Chinese Ministry of Health [8]. Patients with scarlet fever
or pharyngitis from whom GAS was isolated were identi-
fied as GAS culture-positive patients.
Model for cases numbers estimation
Previous studies had used the multiplier model to esti-
mate the burden of pandemic (H1N1) 2009 in China
and USA [9, 10], and hand, foot and mouth disease in
China [11]. In this study, the multiplier model was used
to estimate the burden of GAS pharyngitis among
children aged 0–14 years in Beijing. To estimate the
total number of cases of GAS culture-positive pharyn-
gitis, we built the multiplier model to adjust the count
of laboratory-confirmed cases from GAS surveillances in
Beijing for the following steps: medical care seeking (B
to A), population coverage of GAS surveillances in
Beijing (C to B), collection of samples (D to C), and la-
boratory detection of GAS (E to D) (see Fig. 1). At each
step, data for parameter estimations was identified as a
range of proportions observed in previous studies, sur-
veys and surveillances.
Because NNIDSS covered all hospitals and all popula-
tion in Beijing, population coverage of GAS surveillances
among scarlet fever cases was calculated by dividing re-
ported number of clinical cases of scarlet fever from
GAS surveillances by reported number from NNIDSS in
Beijing. In this study, we assumed that population cover-
age among cases of scarlet fever was equal to that
among cases of pharyngitis.
The number of cases of GAS culture-positive pharyn-
gitis was calculated using: (1) Na was age-specific re-
ported number of clinical cases from GAS surveillances.
(2) Ra was age-specific GAS culture-positive rate by
GAS surveillance in Beijing. (3) Ca was age-specific con-
sultation rate. Consultation rate was calculated by the
function (1-proportion of patient who do not visit any
Fig. 1 Model parameters for estimating the burden of GAS
pharyngitis in Beijing, 2012–2014. Note: A, Total no. cases of GAS
culture-positive pharyngitis in Beijing; B, Cases refer to hospitals in
Beijing = A* Consultation rate; C, Cases refer to sentinel hospitals
of GAS surveillances in Beijing = B*Population coverage of GAS
surveillances in Beijing; D, Cases for which specimens were
successfully collected = C*Sampling success rate; E, Predicted
positive specimens that were correctly identified by laboratory
tests = D*Test sensitivity
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health institutions), based on literature data from the
Fourth National Health Services Survey of China in
2008, which showed that among children aged 0–4 and
5–14 years, 27.3 and 40.3 % of patients do not visit any
health institutions when they were ill [12]. Accordingly,
consultation rate among children aged 0–4 and 5–14
years was 72.7 and 59.7 % respectively. (4) Pa, age-
specific population coverage of GAS surveillances. (5) s
was the success rate for sampling swab samples, ranged
from 80 to 90 %, and it was obtained from a study from
Beijing [9]. (6) t was the test sensitivity of throat culture,
ranged from 75.2 to 97.1 %, and it was obtained from a
review study of 13 published literatures [13] (see Eq. 1).
Total number of cases of GAS culture‐positive pharyngitis
¼
X Na  Ra
Ca  Pa  s  t
ð1Þ
The number of clinical cases of pharyngitis was calcu-
lated using: (1) Na, (2) Ca, and (3) Pa (see Eq. 2).
Total number of clinical cases of pharyngitis
¼
X Na
Ca  Pa ð2Þ
The number of outpatient visits for GAS culture-
positive pharyngitis was calculated using: (1) Na, (2) Ra,
(3) Pa, (4) s, and (5) t (see Eq. 3).
Total number of outpatient visits for GAS culture‐
positive pharyngitis ¼
X Na  Ra
Pa  s  t
ð3Þ
The number of outpatient visits for clinical cases of
pharyngitis was a calculation of reported number of clin-
ical cases from GAS surveillances divided by population
coverage of GAS surveillances (see Eq. 4).





The same approach was used to estimate the total
number of cases of GAS culture-positive scarlet fever,
the total number of clinical cases of scarlet fever, the
total number of outpatient visits for GAS culture-
positive scarlet fever, and the total number of outpatient
visits for clinical cases of scarlet fever.
Annual incidence rate was equal to the estimated
number of cases divided by population number from the
2010 National Population Census in Beijing, China [14].
Data from the census showed that there were 1,687,437
persons in the age group of 0–14 in Beijing, of which
those aged 0–4 years accounted for 40.65 %.
Data analysis
Ninety-five percent confidence intervals (CIs) for popu-
lation coverage and GAS culture-positive rate of GAS
surveillances by age groups were calculated using the
normal approximation. Difference among the subgroups
were tested by Pearson’s Chi-square test with a two-
sided p value <0.05 as the statistical significance level.
Data analyses were carried out using SPSS Version 13.0
(SPSS Inc, Chicago, IL). Ninety-five percent CIs for esti-
mated numbers of cases and annual incidence rate were
determined by Monte Carlo simulation, using a multi-
plier model (Impact 2009, version 1.0) by United States
Centers for Disease Control and Prevention.
Results
Data from NNIDSS and GAS surveillances in Beijing
The reported numbers of clinical cases of scarlet fever
and pharyngitis from GAS surveillances and NNIDSS by
years and age groups are shown in Table 1. From 2012
to 2014, a total of 9078 clinical cases of scarlet fever
aged 0–14 years were reported from NNIDSS in Beijing,
26.1 % of whom were children aged 0–4 years, and
73.9 % were between the age of 5 and 14 years.
During the same period, a total of 4093 clinical cases
of scarlet fever and 447,232 ones of pharyngitis were re-
ported from GAS surveillances in Beijing. Of the 4093
clinical cases of scarlet fever, 28.3 % were children aged
0–4 years and 71.7 % were between the age of 5 and
14 years. Of the 447,232 clinical cases of pharyngitis,
51.7 % were children aged 0–4 years and 48.3 % were
between the age of five and fourteen years.
Population coverage of GAS surveillances in Beijing
Using the surveillance data from NNIDSS and GAS sur-
veillances, we estimated the population coverage of GAS
surveillances among children aged 0–4 years and 5–14
years in Beijing, respectively. Because the number of
sentinel hospitals was cut down from 36 to 17, the
population coverage of GAS surveillances in 2014 was
significantly lower than that in 2012 and 2013 (see
Table 2).
GAS culture-positive rate of GAS surveillances in Beijing
Bacterial surveillance data for GAS showed that the
overall positive rate of GAS causing scarlet fever was
significantly higher than pharyngits during the 3 years
(p < 0.05). The lower rate of GAS causing pharyngits in
2013 compared to 2012 and 2014 was statistically signifi-
cant (p < 0.05), but no significant difference of positive
rate of GAS causing scarlet fever was found between the
3 years (p > 0.05). With respect to the difference between
the two age groups, we observed higher positive rate of
GAS causing pharyngits among children aged 5–14 years
in all the 3 years (p < 0.05). Nonetheless, no significant
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association between age and positive rate of GAS causing
scarlet fever existed in any of 3 years (p > 0.05) (see
Table 3).
Numbers of clinical cases and GAS culture-positive cases
Using the multiplier model, we estimated that there were
398,720 clinical cases of pharyngitis in 2012, 467,670
cases in 2013 and 642,410 cases in 2014, with an annual
incidence rate of 23628.7, 27714.8 and 38070.2 cases per
100,000 children, respectively. Of these clinical cases, a
total of 50,499, 19,258, and 66,172 pharyngitis cases
were GAS culture-positive during 2012 to 2014, with an
annual incidence rate of 2992.6, 1141.3 and 3921.5 cases
per 100,000 children, respectively. The incidence of GAS
culture-positive pharyngitis was statistically significantly
lower in 2013 than in 2012 and 2014 (p < 0.05), but no
significant difference was found between 2012 and 2014
(p > 0.05). With respect to the difference between the
two age groups, we observed a higher risk for incidence
of GAS culture-positive pharyngitis among children aged
5–14 years in all the 3 years (4273.5 vs. 1122.2 cases per
100,000 children in 2012, 1636.4 vs. 418.2 cases per
100,000 children in 2013, and 5728.5 vs. 1282.8 cases
per 100,000 children in 2014, p < 0.05). The annual inci-
dence rate of GAS culture-positive pharyngitis was more
than 10 times higher than that of scarlet fever during
the 3 years (2992.6 vs. 206.9 cases per 100,000 children
in 2012, 1141.3 vs. 101.7 cases per 100,000 children in
2013, and 3921.5 vs. 220.6 cases per 100,000 children in
2014, p < 0.05) (see Table 4).
Outpatient visits for clinical cases and GAS
culture-positive cases
As shown in Table 5, we estimated that there were
262,760, 305,760, and 419,590 outpatient visits for clin-
ical cases of pharyngitis during 2012 to 2014, with an
Table 1 Reported numbers of clinical cases of scarlet fever and pharyngitis from GAS surveillances and NNIDSS by age groups,
Beijing, 2012–2014
Year Age group Reported number of clinical
cases of scarlet fever from
GAS surveillances
Reported number of clinical
cases of pharyngitis from
GAS surveillances
Reported number of clinical
cases of scarlet fever from
NNIDSS
2012 0–4 573 79280 998
5–14 1226 70872 2154
Overall(0–14) 1799 150152 3152
2013 0–4 286 80595 526
5–14 712 74356 1503
Overall(0–14) 998 154951 2029
2014 0–4 299 71132 842
5–14 997 70997 3055
Overall(0–14) 1296 142129 3897
2012–2014 0–4 1158 231007 2366
5–14 2935 216225 6712
Overall(0–14) 4093 447232 9078
Table 2 Estimates of population coverage of GAS surveillances by age groups, Beijing, 2012–2014
Year Age group Reported number of
clinical cases of scarlet
fever from GAS surveillances
Reported number of
clinical cases of scarlet
fever from NNIDSS
Population coverage of GAS surveillances
Proportion (%) 95 % CI
2012 0–4 573 998 57.4 54.3 60.5
5–14 1226 2154 56.9 54.8 59.0
Overall(0–14) 1799 3152 57.1 55.3 58.8
2013 0–4 286 526 54.4 50.1 58.6
5–14 712 1503 47.4 44.8 49.9
Overall(0–14) 998 2029 49.2 47.0 51.4
2014 0–4 299 842 35.5 32.3 38.7
5–14 997 3055 32.6 31.0 34.3
Overall(0–14) 1296 3897 33.3 31.8 34.7
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annual incidence rate of 15571.5, 18119.8 and 24865.5
cases per 100,000 children, respectively. Of these out-
patient visits for clinical cases, a total of 31,148, 11,870
and 40,648 cases of pharyngitis were GAS culture-
positive during the same period, with an annual inci-
dence rate of 1845.9, 703.4, and 2408.9 cases per
100,000 children, respectively. The incidence of out-
patient visits for GAS culture-positive pharyngitis was
statistically significantly lower in 2013 than in 2012 and
2014 (p < 0.05), but no significant difference was found
between 2012 and 2014 (p > 0.05). Compared to children
aged 0–4 years, those aged 5–14 years had a higher risk
of outpatient visits for GAS culture-positive pharyngitis
in all the 3 years (2551.3 vs. 815.8 cases per 100,000 chil-
dren in 2012, 976.9 vs. 304 cases per 100,000 children in
2013, and 3419.9 vs. 932.6 cases per 100,000 children in
2014, p < 0.05). The incidence of outpatient visits for
GAS culture-positive pharyngitis was significantly higher
than that of scarlet fever during the 3 years (1845.9 vs.
130 cases per 100,000 children in 2012, 703.4 vs. 231.6
cases per 100,000 children in 2013, and 2408.9 vs. 136.9
cases per 100,000 children in 2014, p < 0.05) (see
Table 5).
Discussion
This is the first study to estimate the incidence of clin-
ical cases of pharyngitis and GAS culture-positive pha-
ryngitis among children in China. It was estimated that
an average of 502933.3 clinical cases of pharyngitis oc-
curred in children aged 0–14 years with about 29.8
(95 % CI: 28.3–31.3) cases per 100 child-years in Beijing,
from 2012 to 2014. Although pharyngitis may seem rela-
tively benign and unimportant, our study found that it
caused as many as 329,370 outpatient visits each year
with about 19.5 (95 % CI: 18.5–20.5) cases per 100
child-years in Beijing during 2012 to 2014, which indi-
cated enormous use of health resources and medical
costs. Our results are consistent with data from the
National Ambulatory Medical Care Survey in United
States, which reported that pharyngitis are responsible
for 20 visits to a physician per 100 population annually
in the United States [15]. These data highlighted that
pharyngitis is a very common presenting symptom for
seeking medications among children in Beijing, China.
In our study, we estimated that an average of 45309.7
pharyngitis cases were laboratory confirmed per year
from 2012 to 2014 in Beijing, with an annual incidence
rate of 2.7 (95 % CI: 2.0–3.3) per 100 person-years for
children, respectively, similar to the rate of GAS pharyn-
gitis reported from a study in Europe (3.9 per 100 per-
sons per year) [16], but lower than recently reported
rates in Australia (13 per 100 person-years in 2001/2002
[17], and 14 per 100 person-years in 2001 [18]), and Fiji
(14.7 per 100 person-years in 2006 [19]). In a peri-urban
population of northern India, the incidence of GAS
pharyngitis among 5–15-year-old schoolchildren, with
Table 3 GAS culture-positive rate of GAS surveillances in Beijing by age groups, Beijing, 2012–2014
Year Clinical manifestations Age group Samples no. GAS culture-positive rate
Proportion (%) 95 % CI
2012 Scarlet fever 0–4 71 45.1 33.5 56.6
5–14 154 53.2 45.4 61.1
Overall(0–14) 225 50.7 44.1 57.2
Pharyngitis 0–4 1012 3.0 1.9 4.0
5–14 906 14.9 12.6 17.2
Overall(0–14) 1918 8.6 7.3 9.9
2013 Scarlet fever 0–4 50 36.0 22.7 49.3
5–14 110 39.1 30.0 48.2
Overall(0–14) 160 38.1 30.6 45.7
Pharyngitis 0–4 1382 1.0 0.5 1.5
5–14 1295 4.6 3.4 5.7
Overall(0–14) 2677 2.7 2.1 3.3
2014 Scarlet fever 0–4 50 42.0 28.3 55.7
5–14 216 43.5 36.9 50.1
Overall(0–14) 266 43.2 37.3 49.2
Pharyngitis 0–4 1479 2.3 1.5 3.1
5–14 1472 11.4 9.8 13.0
Overall(0–14) 2951 6.8 5.9 7.8
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Table 4 Estimated numbers of clinical cases and GAS culture-positive cases, Beijing, 2012–2014
Year Clinical
manifestations
Age groups Clinical cases GAS culture-positive cases
n 95 % CI Annual incidence rate 95 % CI n 95 % CI Annual incidence rate 95 % CI
2012 Scarlet fever 0–4 1374.5 1289.8 1459.2 200.4 188.0 212.8 848.8 558.4 1139.3 123.8 81.4 166.1
5–14 3607.6 3452.8 3762.4 360.2 344.7 375.7 2642.1 2003.3 3280.9 263.8 200.0 327.6
Overall(0–14) 4982.1 4806.0 5158.2 295.2 284.8 305.7 3490.9 2712.2 4269.6 206.9 160.7 253.0
Pharyngitis 0–4 190170.0 178448.6 201891.4 27726.4 26017.5 29435.4 7696.7 4258.0 11135.4 1122.2 620.8 1623.5
5–14 208550.0 199602.5 217497.5 20822.6 19929.2 21715.9 42802.0 32187.9 53416.1 4273.5 3213.8 5333.3
Overall(0–14) 398720.0 384004.8 413435.2 23628.7 22756.7 24500.8 50499.0 38576.9 62421.1 2992.6 2286.1 3699.2
2013 Scarlet fever 0–4 725.1 660.7 789.5 105.7 96.3 115.1 360.6 199.1 522.1 52.6 29.0 76.1
5–14 2521.7 2368.5 2674.9 251.8 236.5 267.1 1355.8 920.0 1791.6 135.4 91.9 178.9
Overall(0–14) 3246.7 3080.6 3412.8 192.4 182.6 202.2 1716.4 1213.6 2219.2 101.7 71.9 131.5
Pharyngitis 0–4 204320.0 186174.5 222465.5 29789.5 27143.9 32435.0 2868.5 1098.3 4638.7 418.2 160.1 676.3
5–14 263340.0 247341.8 279338.2 26293.1 24695.7 27890.4 16389.0 10957.0 21821.0 1636.4 1094.0 2178.7
Overall(0–14) 467670.0 443493.5 491846.5 27714.8 26282.1 29147.6 19258.0 13397.0 25119.0 1141.3 793.9 1488.6
2014 Scarlet fever 0–4 1166.2 1043.0 1289.4 170.0 152.1 188.0 678.0 396.4 959.7 98.9 57.8 139.9
5–14 5125.4 4829.3 5421.5 511.7 482.2 541.3 3044.8 2316.5 3773.1 304.0 231.3 376.7
Overall(0–14) 6291.5 5974.1 6608.9 372.8 354.0 391.7 3722.8 2881.0 4564.6 220.6 170.7 270.5
Pharyngitis 0–4 277430.0 248129.5 306730.5 40448.8 36176.8 44720.7 8798.4 5111.4 12485.4 1282.8 745.2 1820.4
5–14 364980.0 343892.7 386067.3 36441.3 34335.8 38546.7 57374.0 43707.7 71040.3 5728.5 4364.0 7093.0
Overall(0–14) 642410.0 606815.7 678004.3 38070.2 35960.8 40179.5 66172.0 51279.1 81064.9 3921.5 3038.9 4804.0
Average: 2012−2014 Scarlet fever 0−4 1088.6 997.8 1179.3 158.7 145.5 171.9 629.2 384.6 873.7 91.7 56.1 127.4
5−14 3751.6 3550.2 3952.9 374.6 354.5 394.7 2347.6 1746.6 2948.5 234.4 174.4 294.4
Overall(0–14) 4840.1 4620.2 5060.0 286.8 273.8 299.9 2976.7 2268.9 3684.5 176.4 134.5 218.3
Pharyngitis 0−4 223973.3 204250.9 243695.8 32654.9 29779.4 35530.4 6454.5 3489.2 9419.8 941.1 508.7 1373.4
5−14 278956.7 263612.3 294301.0 27852.3 26320.2 29384.4 38855.0 28950.9 48759.1 3879.5 2890.6 4868.3














Table 5 Estimates of outpatient visits for clinical cases and GAS culture-positive cases, Beijing, 2012−2014
Year Clinical
manifestations
Age groups Clinical cases GAS culture−positive cases
n 95 % CI Annual incidence rate 95 % CI n 95 % CI Annual incidence rate 95 % CI
2012 Scarlet fever 0−4 999.3 937.7 1060.8 145.7 136.7 154.7 617.1 405.9 828.3 90.0 59.2 120.8
5−14 2153.7 2061.3 2246.1 215.0 205.8 224.3 1577.3 1195.9 1958.7 157.5 119.4 195.6
Overall(0–14) 3153.0 3042.2 3263.8 186.9 180.3 193.4 2194.4 1705.0 2683.8 130.0 101.0 159.0
Pharyngitis 0−4 138260.0 129738.6 146781.4 20158.0 18915.6 21400.5 5595.5 3095.6 8095.4 815.8 451.3 1180.3
5−14 124500.0 119158.3 129841.7 12430.6 11897.3 12964.0 25553.0 19216.4 31889.6 2551.3 1918.7 3184.0
Overall(0–14) 262760.0 252722.4 272797.6 15571.5 14976.7 16166.4 31148.0 23795.2 38500.8 1845.9 1410.1 2281.6
2013 Scarlet fever 0−4 527.1 480.3 573.9 76.9 70.0 83.7 262.2 144.8 379.5 38.2 21.1 55.3
5−14 1505.4 1413.9 1596.9 150.3 141.2 159.4 809.4 549.2 1069.6 80.8 54.8 106.8
Overall(0–14) 2032.6 1929.9 2135.3 120.5 114.4 126.5 1071.6 759.5 1383.7 63.5 45.0 82.0
Pharyngitis 0−4 148540.0 135348.2 161731.8 21656.8 19733.5 23580.2 2085.4 798.4 3372.4 304.0 116.4 491.7
5−14 157220.0 147669.1 166770.9 15697.6 14744.0 16651.2 9784.3 6541.4 13027.2 976.9 653.1 1300.7
Overall(0–14) 305760.0 289483.0 322037.0 18119.8 17155.2 19084.4 11870.0 8276.2 15463.8 703.4 490.5 916.4
2014 Scarlet fever 0−4 847.8 758.3 937.3 123.6 110.6 136.7 492.9 288.2 697.7 71.9 42.0 101.7
5−14 3059.8 2883.0 3236.6 305.5 287.9 323.2 1817.7 1382.9 2252.5 181.5 138.1 224.9
Overall(0–14) 3907.6 3711.8 4103.4 231.6 220.0 243.2 2310.6 1787.2 2834.0 136.9 105.9 167.9
Pharyngitis 0−4 201690.0 180388.5 222991.5 29406.0 26300.3 32511.7 6396.4 3715.9 9076.9 932.6 541.8 1323.4
5−14 217890.0 205300.9 230479.1 21755.1 20498.2 23012.1 34252.0 26093.2 42410.8 3419.9 2605.3 4234.5
Overall(0–14) 419590.0 395166.5 444013.5 24865.5 23418.1 26312.9 40648.0 31534.6 49761.4 2408.9 1868.8 2948.9
Average: 2012−2014 Scarlet fever 0−4 791.4 725.4 857.4 115.4 105.8 125.0 457.4 279.6 635.2 66.7 40.8 92.6
5−14 2239.6 2119.4 2359.8 223.6 211.6 235.6 1401.5 1042.7 1760.3 139.9 104.1 175.8
Overall(0–14) 3031.1 2894.6 3167.5 179.6 171.5 187.7 1858.9 1417.2 2300.5 110.2 84.0 136.3
Pharyngitis 0−4 162830.0 148491.8 177168.2 23740.3 21649.8 25830.8 4692.4 2536.7 6848.2 684.1 369.8 998.5
5−14 166536.7 157376.1 175697.3 16627.8 15713.1 17542.4 23196.4 17283.7 29109.2 2316.0 1725.7 2906.4














an estimation of 95 per 100 person-years in 1995/1996
[20], was significantly higher than our estimation in
Beijing. There were two reasons which may partially ex-
plain the lower rates of GAS pharyngitis in Beijing. First,
GAS-related diseases are highly transmissible within
populations characterized by crowding, limited access to
hygiene and inadequate medical care [20]. As one of the
most developed regions in China, Beijing has undergone
epidemiological transition from communicable to non-
communicable diseases as the predominant causes of
morbidity and mortality. Scarlet fever is usually used as
a proxy of GAS-related diseases because of its distinctive
clinical features. During the period from 1949 to 2006,
the incidence of scarlet fever has remarkably fallen from
488.3 to 1.86 cases per 100000 persons among all age
population in Beijing [21]. Second, although immunity
to GAS is emm-type specific [22], most of GAS samples
from Beijing GAS surveillances were indentified as
emm-1 and 12 types, from 2011 to 2014 [23]. Therefore,
a large percentage of Beijing population had become im-
mune to GAS infection from 2012 to 2014 because of
the 2011 GAS epidemic in Beijing [7].
GAS causes a broad spectrum of diseases, ranging
from mild superficial infections of the throat or skin to
severe invasive infections and the post-streptococcal
complications of acute rheumatic fever and acute post-
streptococcal glomerulonephritis. In China, scarlet fever
is the only notifiable disease among these GAS diseases
according to the Law, but other GAS related infections
are not notifiable and there are very few active surveil-
lance systems. In our study, we found that the incidence
of GAS pharyngitis was more than 10 times higher than
that of scarlet fever. Accordingly, GAS pharyngitis
caused more outpatient visits than GAS scarlet fever
among children in Beijing. These results indicated that
the disease burden of GAS pharyngitis has been signifi-
cant, and posing great threats to the health of children
in Beijing. Therefore, more epidemiological studies and
surveillance of other GAS related infections should be
developed in Beijing, and other regions in China.
Our result demonstrated that the incidence of GAS
pharyngitis among children aged 5–15 years was heavier
than in preschool children aged 0–4 years due to the
distinct difference of GAS culture-positive rates across
the two agegroups. The result confirmed that disease
burden of GAS is higher from 5–15 years than with
younger children. However, the GAS culture-positive
rates of scarlet fever didn’t vary smililarly. Unlike clinical
cases of pharyngitis, clinical cases of scarlet fever had
more distinctive clinical features and specific case defin-
ition in this study. Thus it was easily for clinicians to
diagnose these cases without laboratory tests. Accord-
ingly, the GAS culture-positive rate of scarlet fever was
much higher than that of pharyngitis in all agegroups,
and only a small difference was observed between the
two agegroups.
In this study, we observed the significant variation in
yearly incidence, which may be explained by epidemic
period of GAS. As a proxy of GAS-related diseases, epi-
demiological data showed that the epidemic period of
scarlet fever was about 6–8 years in Beijing [21]. The
factors including genetic variation, environmental fac-
tors, and host immune status might have contributed to
the epidemic period [7]. But further studies should be
conducted to analyse these factors.
Our study has several limitations. First, because pha-
ryngitis was not a notifiable disease in Beijing, some re-
cords for pharyngitis outpatient visits might be omitted
by clinicians when they were busy to diagnose and treat
the patients. Therefore, the estimated incidence for GAS
pharyngitis in our study might have been underesti-
mated. Second, there was no survey of health-seeking
behavior among patients of GAS pharyngitis, so we have
to use the age-specific consultation rate of all diseases
from the Fourth National Health Services Survey of
China (NHSS) in 2008. Nevertheless, the consultation
rate of patient-defined Hand, Foot, and Mouse disease
was estimated at 75.1 % among children under 5 years
of age in Beijing, which is almost equal to the rate of all
diseases at 72.7 % from NHSS [11]. The finding may in-
dicate that the consultation rates for parameter estima-
tions were acceptable and reliable. Third, as a model
study, additional data from surveys of health-seeking be-
havior among patients of GAS diseases and reporting
quality of physician practice could help refine the par-
ameter estimates [10]. Although the multiplier model
provided a quicker and more representative results than
population-based surveys, a prospective, cohort study in
China is needed to confirm our estimations since the
model has not been used to estimate GAS burden.
Conclusions
In conclusion, we estimated an average of 29.8 clinical
cases of pharyngitis and 2.7 cases of GAS culture-positive
pharyngitis per 100 person-years among children aged 0–
14 years, resulting in a large number of outpatient visits
from 2012 to 2014 in Beijing, China. These estimates sug-
gest that the disease burden of GAS pharyngitis has been
significant, and posing great threats to the health of chil-
dren in China. More epidemiological studies and surveil-
lances should be developed to estimate the burden of GAS
related diseases in Beijing, and other regions in China.
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